The role of apomorphine SL in the treatment of erectile dysfunction

Research output: Contribution to journalArticle

Abstract

Epidemiological data indicate that erectile dysfunction (ED) affects over 140 million men worldwide, with the highest prevalence in men over 60 years. While the condition is often associated with coronary artery disease, hyperlipidemia, hypertension and diabetes, and may be a marker for these conditions, most men who present with ED for treatment have mild to moderate dysfunction. Treatment guidelines developed by an international, multidisciplinary panel of experts as a "process of care model for erectile dysfunction" recommend the implementation of oral agents as first-line therapy. Sublingual apomorphine SL is the first medication for the treatment of erectile dysfunction with a central mechanism of action. In clinical studies, apomorphine SL provides clinical erectogenic benefits at 2 and 3 mg doses particularly in those patients with mild to moderate ED. Apomorphine SL has the added advantages of a rapid onset of action, resulting in erection in less than half the time required by sildenafil, and a highly favorable tolerability and safety profile, especially in patients with coronary artery disease receiving nitrates. Apomorphine SL is an important addition to the armamentarium of primary care clinicians and urologists treating male erectile dysfunction, due to enhanced erectile function, speed of onset, convenience of dosing, and favorable side effect profile. Apomorphine SL 2 and 3 mg is an effective first-line treatment option for men presenting with mild to moderate ED, who have a degree of residual erectile function that is inadequate for satisfactory sexual performance.

Original languageEnglish
Pages (from-to)4-11
Number of pages8
JournalEuropean Urology, Supplements
Volume1
Issue number3
DOIs
Publication statusPublished - May 2002

Fingerprint

Apomorphine
Erectile Dysfunction
Therapeutics
Coronary Artery Disease
Hyperlipidemias
Nitrates
Primary Health Care
Guidelines
Hypertension
Safety

Keywords

  • Apomorphine SL
  • Erectile dysfunction
  • Sildenafil

ASJC Scopus subject areas

  • Urology

Cite this

The role of apomorphine SL in the treatment of erectile dysfunction. / Montorsi, Francesco.

In: European Urology, Supplements, Vol. 1, No. 3, 05.2002, p. 4-11.

Research output: Contribution to journalArticle

@article{d45785c0294c4093b574c5b2e92740c9,
title = "The role of apomorphine SL in the treatment of erectile dysfunction",
abstract = "Epidemiological data indicate that erectile dysfunction (ED) affects over 140 million men worldwide, with the highest prevalence in men over 60 years. While the condition is often associated with coronary artery disease, hyperlipidemia, hypertension and diabetes, and may be a marker for these conditions, most men who present with ED for treatment have mild to moderate dysfunction. Treatment guidelines developed by an international, multidisciplinary panel of experts as a {"}process of care model for erectile dysfunction{"} recommend the implementation of oral agents as first-line therapy. Sublingual apomorphine SL is the first medication for the treatment of erectile dysfunction with a central mechanism of action. In clinical studies, apomorphine SL provides clinical erectogenic benefits at 2 and 3 mg doses particularly in those patients with mild to moderate ED. Apomorphine SL has the added advantages of a rapid onset of action, resulting in erection in less than half the time required by sildenafil, and a highly favorable tolerability and safety profile, especially in patients with coronary artery disease receiving nitrates. Apomorphine SL is an important addition to the armamentarium of primary care clinicians and urologists treating male erectile dysfunction, due to enhanced erectile function, speed of onset, convenience of dosing, and favorable side effect profile. Apomorphine SL 2 and 3 mg is an effective first-line treatment option for men presenting with mild to moderate ED, who have a degree of residual erectile function that is inadequate for satisfactory sexual performance.",
keywords = "Apomorphine SL, Erectile dysfunction, Sildenafil",
author = "Francesco Montorsi",
year = "2002",
month = "5",
doi = "10.1016/S1569-9056(02)00008-8",
language = "English",
volume = "1",
pages = "4--11",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The role of apomorphine SL in the treatment of erectile dysfunction

AU - Montorsi, Francesco

PY - 2002/5

Y1 - 2002/5

N2 - Epidemiological data indicate that erectile dysfunction (ED) affects over 140 million men worldwide, with the highest prevalence in men over 60 years. While the condition is often associated with coronary artery disease, hyperlipidemia, hypertension and diabetes, and may be a marker for these conditions, most men who present with ED for treatment have mild to moderate dysfunction. Treatment guidelines developed by an international, multidisciplinary panel of experts as a "process of care model for erectile dysfunction" recommend the implementation of oral agents as first-line therapy. Sublingual apomorphine SL is the first medication for the treatment of erectile dysfunction with a central mechanism of action. In clinical studies, apomorphine SL provides clinical erectogenic benefits at 2 and 3 mg doses particularly in those patients with mild to moderate ED. Apomorphine SL has the added advantages of a rapid onset of action, resulting in erection in less than half the time required by sildenafil, and a highly favorable tolerability and safety profile, especially in patients with coronary artery disease receiving nitrates. Apomorphine SL is an important addition to the armamentarium of primary care clinicians and urologists treating male erectile dysfunction, due to enhanced erectile function, speed of onset, convenience of dosing, and favorable side effect profile. Apomorphine SL 2 and 3 mg is an effective first-line treatment option for men presenting with mild to moderate ED, who have a degree of residual erectile function that is inadequate for satisfactory sexual performance.

AB - Epidemiological data indicate that erectile dysfunction (ED) affects over 140 million men worldwide, with the highest prevalence in men over 60 years. While the condition is often associated with coronary artery disease, hyperlipidemia, hypertension and diabetes, and may be a marker for these conditions, most men who present with ED for treatment have mild to moderate dysfunction. Treatment guidelines developed by an international, multidisciplinary panel of experts as a "process of care model for erectile dysfunction" recommend the implementation of oral agents as first-line therapy. Sublingual apomorphine SL is the first medication for the treatment of erectile dysfunction with a central mechanism of action. In clinical studies, apomorphine SL provides clinical erectogenic benefits at 2 and 3 mg doses particularly in those patients with mild to moderate ED. Apomorphine SL has the added advantages of a rapid onset of action, resulting in erection in less than half the time required by sildenafil, and a highly favorable tolerability and safety profile, especially in patients with coronary artery disease receiving nitrates. Apomorphine SL is an important addition to the armamentarium of primary care clinicians and urologists treating male erectile dysfunction, due to enhanced erectile function, speed of onset, convenience of dosing, and favorable side effect profile. Apomorphine SL 2 and 3 mg is an effective first-line treatment option for men presenting with mild to moderate ED, who have a degree of residual erectile function that is inadequate for satisfactory sexual performance.

KW - Apomorphine SL

KW - Erectile dysfunction

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=0036590009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036590009&partnerID=8YFLogxK

U2 - 10.1016/S1569-9056(02)00008-8

DO - 10.1016/S1569-9056(02)00008-8

M3 - Article

AN - SCOPUS:0036590009

VL - 1

SP - 4

EP - 11

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 3

ER -